Vitamin D (25-OH): Optimal vs Normal Levels
The vitamin D test is cheap, widely ordered and surprisingly variable between laboratories. What the number means, how much to trust it, and where the target ranges come from.
The Short Answer
Serum 25-hydroxyvitamin D is the correct measure of vitamin D status, reflecting both skin synthesis and dietary intake with a half-life of two to three weeks. Conventional interpretation places below 20 ng/mL (50 nmol/L) as inadequate, 20 to 30 ng/mL (50 to 75 nmol/L) as sufficient for bone health in most population guidance, and 30 to 50 ng/mL (75 to 125 nmol/L) as the range most optimisation-oriented practice targets. The two things most people do not know about this test are that inter-laboratory variability has historically been substantial, and that the active hormone, 1,25-dihydroxyvitamin D, is the wrong test for status because it is tightly regulated and can appear normal when stores are low.
Which Test and Why
Vitamin D exists in several measurable forms and only one of them answers the status question.
25-hydroxyvitamin D. The circulating storage form, produced by hepatic hydroxylation. Half-life of two to three weeks, concentrations in the nanogram per millilitre range, and reflective of total supply. This is the status test. Good assays report total 25-hydroxyvitamin D including both D2 and D3 forms, which matters for anyone supplementing D2.
1,25-dihydroxyvitamin D. The active hormone, produced mainly in the kidney under parathyroid hormone control. Half-life of hours, concentrations a thousandfold lower, and homeostatically defended. When stores fall, parathyroid hormone rises and drives conversion, so the active hormone can be normal or even elevated in the presence of low stores. Ordering this test for status assessment is a common and misleading error. It has legitimate uses in specific clinical contexts, including granulomatous conditions and calcium handling problems.
Free and bioavailable 25-hydroxyvitamin D. Most circulating 25-hydroxyvitamin D is bound to vitamin D binding protein. Free and bioavailable fractions can be measured or calculated and may explain part of the discrepancy between total concentrations and clinical picture, particularly across population groups with differing binding protein genetics. This is a research-forward area rather than routine practice.
Parathyroid hormone. Not a vitamin D test, but the most useful companion. A rising parathyroid hormone is the functional signal that vitamin D supply is inadequate for calcium handling, and the point at which it stabilises is one of the more defensible ways to define sufficiency.
Where the Target Ranges Come From
The disagreement between guidance bodies is genuine and reflects different questions rather than different data.
Population-level bone health guidance targets the concentration at which skeletal outcomes are adequate for most people, and lands around 20 ng/mL (50 nmol/L) as a population sufficiency figure, with 30 ng/mL used by some bodies as an individual sufficiency threshold.
Endocrine and clinical guidance has generally used 30 ng/mL (75 nmol/L) as the sufficiency threshold, partly on the basis of parathyroid hormone suppression and calcium absorption efficiency plateauing around that point.
Optimisation-oriented practice targets 30 to 50 ng/mL, drawing on association data for immune, metabolic and mood outcomes rather than on randomised outcome data, which is a weaker evidence base and should be described as such.
Above 60 ng/mL (150 nmol/L) there is no demonstrated additional benefit. Above roughly 100 ng/mL (250 nmol/L), calcium handling concerns become real, and sustained very high intake is the route there.
The honest summary: 30 to 40 ng/mL is a defensible target, 30 ng/mL is where the strongest evidence sits, and pursuing 70 or 80 ng/mL is unsupported by outcome data.
Assay Variability: The Part Nobody Mentions
Vitamin D assays have a difficult analytical history. Different immunoassay platforms and mass spectrometry methods have produced meaningfully different results on the same sample, with discrepancies large enough to move a person across a decision threshold.
International standardisation programmes have improved this substantially, and modern accredited laboratories using standardised methods agree far better than they did a decade ago. Residual differences remain, particularly for immunoassays with samples containing D2 or with unusual binding protein concentrations.
The practical consequences are simple. Use the same laboratory for repeat testing. Regard a value close to a decision threshold as approximate rather than definitive. And be sceptical of comparisons between a result from one provider and a result from another, especially where one is a fingerprick home test and the other a venous laboratory sample.
Interpreting a Value in Context
The same number means different things depending on when and in whom it was measured.
- Season. Above roughly 37 degrees latitude, winter skin synthesis is negligible. A late-summer value is a personal maximum; a late-winter value is a personal minimum. A single mid-range summer result can conceal an inadequate winter trough.
- Body composition. Adipose tissue sequesters vitamin D, so a higher body mass generally requires a higher intake for the same serum concentration.
- Skin pigmentation and age. Both reduce synthesis capacity for a given ultraviolet exposure, and skin synthesis declines substantially with age.
- Malabsorption and gastrointestinal surgery. Reduce uptake of a fat-soluble vitamin.
- Medications. Some anticonvulsants and glucocorticoids accelerate vitamin D catabolism.
- Recent bolus dosing. A large single dose in the preceding weeks inflates the value relative to habitual status.
A Testing and Titration Protocol
Vitamin D is one of the few nutrients where individual response to a given dose varies severalfold, which makes titration to measurement genuinely valuable rather than merely tidy.
- Baseline. Measure 25-hydroxyvitamin D, ideally with parathyroid hormone and calcium if the value is low or the picture is unclear.
- Adjust. Start or change the daily dose. Roughly 1,000 IU per day raises serum concentration by around 5 to 10 ng/mL in an average adult, with diminishing returns at higher intakes.
- Re-measure at eight to twelve weeks. Serum concentrations take that long to plateau on a new dose.
- Maintain and monitor twice yearly. Late winter and late summer capture the annual range. If only one test per year is possible, late winter is more informative.
- Re-evaluate on context change. Relocation, significant weight change, a new medication or a change in sun behaviour all shift the dose required.
Anything unexpected, particularly a high value, elevated calcium, or a low value that does not respond to supplementation, belongs with a clinician. Non-response usually indicates absorption, adherence or an underlying issue rather than a need for more.
The AEONNN Perspective
Vitamin D is the clearest example in AEONNN of a recommendation that should be titrated rather than prescribed. Individual response to a fixed dose varies severalfold, which means a static recommendation is wrong for most people and only measurement resolves it. In Discovered Mode the platform reasons from latitude, season, reported sun exposure, skin tone, age and body composition to a sensible starting range; in Synched Mode with a connected result it titrates.
The Quality layer matters here in an unusual form: assay variability. AEONNN regards a value near a decision threshold as approximate and prefers within-laboratory comparison over cross-provider comparison, because the analytical history of this test genuinely warrants it.
Contingency handles what makes this marker distinctive, which is that its correct target dose moves with the calendar and with location. A member who relocates or whose season changes has a stale dose within weeks, and noticing that without being asked is exactly what the Shield architecture is designed to do.
Pillar Matrix mapping
Inflammation and Immune Defense, Structural and Musculoskeletal Support, Metabolic and Cardiovascular Health
Database Matrix layers
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Regulatory Layer (EFSA, FDA, EMA)
- Population Layer (UK Biobank, NHANES)
Frequently Asked
Which vitamin D test should I order?
Serum 25-hydroxyvitamin D, which measures the storage form and reflects total supply. The active hormone, 1,25-dihydroxyvitamin D, is the wrong test for status because it is tightly regulated and can be normal when stores are low.
What is the optimal 25-OH vitamin D level?
Above 30 ng/mL (75 nmol/L) is where the strongest evidence sits, with 30 to 40 ng/mL a defensible optimisation target. Above 60 ng/mL there is no demonstrated additional benefit, and above roughly 100 ng/mL calcium handling becomes a genuine concern.
Why do different labs give different vitamin D results?
Vitamin D assays have a history of inter-method variability large enough to move a value across a threshold. Standardisation programmes have improved this considerably, but same-laboratory comparison remains the sensible practice for tracking.
When in the year should vitamin D be tested?
Twice yearly, in late winter and late summer, captures the annual minimum and maximum. If only one test is possible, late winter is more informative because it reveals the trough.
How long after changing dose should I retest?
Eight to twelve weeks. Serum 25-hydroxyvitamin D has a half-life of two to three weeks and takes that long to plateau on a new intake.
Should parathyroid hormone be measured too?
It is the most useful companion test. A rising parathyroid hormone is the functional signal that vitamin D supply is inadequate for calcium handling, and its stabilisation is one of the more defensible definitions of sufficiency.
Why is my vitamin D still low despite supplementing?
Common explanations include absorption issues, adherence, insufficient dose for body mass since adipose tissue sequesters vitamin D, taking it without fat, or medications that accelerate catabolism. Persistent non-response warrants clinical assessment.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.